Enzyme replacement therapy for lysosomal storage disorders in India by unknown
SPEAKER PRESENTATION Open Access
Enzyme replacement therapy for lysosomal
storage disorders in India
Mamta Muranjan
From International Conference on Human Genetics and 39th Annual Meeting of the Indian Society of
Human Genetics (ISHG)
Ahmadabad, India. 23-25 January 2013
Lysosomal storage disorders (LSD) are a heterogeneous
group of inherited metabolic disorders with a combined
frequency of 1 in 5000 affected live births. The common-
est pathogenic mechanism is qualitative or quantitative
deficiency of one of the 50 known lysosomal enzymes
(acid hydrolases) involved in the catabolism of a variety
of molecules. The outcome of this deficiency is progres-
sive accumulation of partially degraded compounds
which stealthily leads to multiorgan dysfunction.
Unlike many inherited metabolic disorders, diet plays no
role in the control of LSD. However treatment in the form
of Enzyme replacement therapy (ERT) is available for a
few disorders. The diseases for which ERT is currently the
standard of care are Gaucher disease (Imiglucerase,
Velaglucerase, Taliglucerase), MPS I (Laronidase), MPS II
(Idursulfase), Pompe disease (Alglucosidase alpha), Fabry
disease (Agalsidase beta, Agalsidase alfa) and MPS VI
(Galsulfase). These drugs are human recombinant
products manufactured in in-vitro tissue culture systems.
ERT alters the natural history of these diseases and
reverses many of the symptoms. However, as the drugs do
not penetrate the blood-brain barrier, there is no impact
on CNS disease.
Gaucher disease was the first LSD to be treated with
ERT in India since 1999-2000. Six centres in India
located in Mumbai, Delhi, Lucknow and Chennai are
treating patients with ERT.
The major factor limiting widespread access to ERT in
the country is the prohibitive cost, the need to import the
drugs and lack of infrastructure for comprehensive evalua-
tion and supportive care. Access has been facilitated for
Indian patients through a charitable access program
(INCAP). A board of seven National experts and a panel
of International experts constitute the Indian Medical
Advisory Board (IMAB) to screen patients for eligibility on
the basis of pre-determined objective criteria. The experts
also provide guidance for evaluation and management of
LSD. To date approximately 60 individuals with Gaucher
diseases are receiving ERT in India. Some of these have
been receiving ERT for more than 10 years and are young
adults pursuing graduate level academics. Additionally, 20
patients with MPS I, two with Fabry and 20 with classic
infantile Pompe are receiving ERT. ERT is currently not
available for MPS II and MPS VI in India.
Twelve individuals with Gaucher disease (10 with type I)
have been treated with Imiglucerase. Of these, one with
severe disease resulting in hepato-pulmonary syndrome
expired and one was transitioned to oral substrate reduc-
tion therapy.
Published: 21 January 2014
doi:10.1186/1755-8166-7-S1-I29
Cite this article as: Muranjan: Enzyme replacement therapy for
lysosomal storage disorders in India. Molecular Cytogenetics 2014
7(Suppl 1):I29.
Correspondence: muranjanmamta@rediffmail.com
Genetic Division, Depart of Pediatrics, KEM Hospital, Parel, Mumbai-400012,
India
Muranjan Molecular Cytogenetics 2014, 7(Suppl 1):I29
http://www.molecularcytogenetics.org/content/7/S1/I29
© 2014 Muranjan; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
